Research compounds Human randomized trial Metabolic health
Also discussed as: Long-acting amylin analogue
What it is and how it works
Cagrilintide is a long-acting amylin analogue. Amylin-related signaling is involved in appetite and meal-related physiology. Studies of cagrilintide alone and studies of combinations such as CagriSema should remain distinct when interpreting evidence.
Source for the mechanism context →A closer look at the cited evidence
Human randomized trial
This label describes the selected source below. It is not a complete ranking of the literature, a safety score, or an approval status.
- Study or assessment
- Lau et al., 2021 — cagrilintide phase 2 trial
- Design
- Randomized, double-blind, placebo- and active-controlled phase 2 trial; 26 weeks.
- Who or what was studied
- Adults with overweight or obesity meeting the study criteria.
- What was observed
- Cagrilintide groups had greater average weight reduction than placebo; gastrointestinal events were reported.
- Limits of interpretation
- This selected study does not establish regulatory approval or cover every combination product. A phase label describes this study, not necessarily the current stage of development.
What the evidence means
A randomized phase 2 study found weight reduction; combination studies answer different questions from studies of this compound alone.
Approval and regulatory context
FDA identifies cagrilintide as unapproved. Its current alert states that it cannot be used in compounding under federal law.
Safety and uncertainty
The cited study reported gastrointestinal symptoms and injection-site reactions. Trial oversight cannot be assumed for research products sold online.
What remains uncertain
A combination’s results cannot be attributed entirely to one component. Current regulatory context, the exact product, study duration, and safety data must be considered separately from the biological rationale.
These summaries are introductory and are not a complete account of the literature, adverse effects, contraindications, or interactions. Absence of a listed risk does not mean absence of risk. Different compounds, formulations, and routes cannot be treated as interchangeable.
Sources behind this overview
Read the source in its full context. Source links support the overview; they do not imply endorsement of this library by the source organization.